CN103565827A - Resveratrol-containing tablets - Google Patents
Resveratrol-containing tablets Download PDFInfo
- Publication number
- CN103565827A CN103565827A CN201310547560.4A CN201310547560A CN103565827A CN 103565827 A CN103565827 A CN 103565827A CN 201310547560 A CN201310547560 A CN 201310547560A CN 103565827 A CN103565827 A CN 103565827A
- Authority
- CN
- China
- Prior art keywords
- calcium
- osteoporosis
- resveratrol
- bone
- tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses resveratrol-containing tablets. The resveratrol-containing tablets are mainly prepared from resveratrol, a calcium preparation and vitamin D.
Description
Technical field
The invention belongs to biomedicine field, be specifically related to a kind of tablet that contains resveratrol.
Background technology
Osteoporosis is a kind of commonly encountered diseases and frequently-occurring disease, and it is seriously threatening middle-aged and elderly people, and especially postmenopausal women is healthy.The complication such as the fracture being caused by osteoporosis, have caused great misery to patient, return society and family and have brought heavy economy and living burden.According to reports, the probability that the osteoporotic women of generation occurred hip, spinal column, forearm or proximal humeral fracture in 10 years later in 50 years old is up to 45%; Be greater than 65 years old old man when unconscious falling, have 87% can cause osteoporotic fracture.China old people's absolute quantity accounts for No. 1 in the world, and along with the growth of growth in the living standard and population life, the aged sharply increases, and therefore, the diagnosis of osteoporosis and control thereof just seem very important.
Osteoporosis can be divided into three major types, and a class is primary osteoporosis, is a kind of physiological degeneration that must occur with advancing age.Equations of The Second Kind is secondary osteoporosis, and it is the osteoporosis of being brought out by some factors such as Other diseases or medicines.The 3rd class is idiopathic osteoporosis disease, is more common in teenager or the adult of 8～14 years old, mostly has family's heredity medical history, and women is more than male.The osteoporosis that gravid woman and women breast-feeding their children occur also can be listed idiopathic osteoporosis in, to cause people's attention.
The main clinical manifestation of osteoporosis and sign are: pain, height shortening, hunchback, fragility fractures and Respiratory Disturbances etc.
1) pain
Pain is the common sympton of osteoporosis, and its reason is mainly that bone resorption increases because bone conversion is high.In bone resorption process, bone trabecular destruction, disappearance, the destruction of subperiosteum cortical bone etc. all can cause general osteodynia, wherein common with lumbago and backache.Another causes that the major reason of pain is fracture.
2) height shortening, hunchback
In silent middle height, shortening or bow-backed, is one of important clinical sign occurring continue lumbago and backache after, and 5-20 centimetre of height shortening is not sometimes etc.
3) fragility fractures
In osteoporosis, skeleton fracture threshold reduces significantly, thereby just easily fractured by slight external force.
4) Respiratory Disturbances
Breast, compression fracture of lumbar vertebra due to serious osteoporosis, usually cause kyphosis, chest deformity, and thoracic cavity capacity obviously declines, and sometimes can cause the changes of function of a plurality of internal organs, and wherein the performance of respiratory system is particularly outstanding.
The final purpose of Prevention and Treatment of Osteoporosis is to reduce the generation of fracture.Adopt clinically and delay and reduce bone loss, strive for recapturing bone amount, increase bone strength and reach this object.The treatment measure of osteoporosis is divided into basic measure and two aspects of Drug therapy.In the measure of basis, bone health supplement are mainly calcium preparation and vitamin D; Drug therapy mainly comprises anti-bone resorption medicine, short bone formation medicine and other drug.
Summary of the invention
The object of the present invention is to provide a kind of tablet that contains resveratrol.
For achieving the above object, the present invention adopts the component of following weight ratio: 5 parts of resveratrols, 50 parts of calcium preparation (in calcium constituent).
Foregoing invention can selectivity interpolation weight portion be the vitamin D of 1000 ius.
Calcium preparation in foregoing invention comprises: one or more in calcium carbonate, calcium gluconate, calcium citrate, calcium lactate, ASPARTIC ACID chelating calcium, calcium acetate.
Edible or the pharmaceutic adjuvant that can also add in foregoing invention comprises: diluent, suspending agent, antioxidant, emulsifying agent, disintegrating agent, adhesive and antiseptic.
The specific embodiment
Embodiment 1: the tablet that contains resveratrol, and its raw material and weight portion are: 5 parts of resveratrols, 50 parts of calcium preparation (in calcium constituent), add appropriate amount of auxiliary materials, make tablet.
Embodiment 2: the tablet that contains resveratrol, and its raw material and weight portion are: 5 parts of resveratrols, 50 parts of calcium preparation (in calcium constituent), vitamin D1 000 iu, add appropriate amount of auxiliary materials, make tablet.
Embodiment 3: effect Journal of Sex Research
The product that inventor makes the specific embodiment of mentioning in content of the present invention, takes effect comparative study with calcium preparation, below enumerates one group of experimental data wherein.
30 male SD rats are divided into 3 groups by body weight homeostatic principle: low calcium matched group, calcium carbonate control group and of the present invention group, each is organized rat ad lib and specially joins accordingly feedstuff.Rat is fed 13 weeks continuously, and after last administration 24 hours, to put to death, separated left side femur, removes skin and flesh, measures the bone density of left side femur.
Result demonstration, in bone density experiment, with the comparison of low calcium matched group, of the present invention group of rat femur quality, calcium content of bone and femur mid point bone density all significantly increase, and show that the present invention has inhibitory action to osteoporosis.
Claims (3)
1. the tablet that contains resveratrol, is characterized in that, comprises the component of following weight ratio: 5 parts of resveratrols, 50 parts of calcium preparation (in calcium constituent).
2. the tablet that contains resveratrol as claimed in claim 1: can also selectivity adding weight portion be the vitamin D of 1000 ius.
3. calcium preparation claimed in claim 1 comprises: one or more in calcium carbonate, calcium gluconate, calcium citrate, calcium lactate, ASPARTIC ACID chelating calcium, calcium acetate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310547560.4A CN103565827A (en) | 2013-11-07 | 2013-11-07 | Resveratrol-containing tablets |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310547560.4A CN103565827A (en) | 2013-11-07 | 2013-11-07 | Resveratrol-containing tablets |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103565827A true CN103565827A (en) | 2014-02-12 |
Family
ID=50039109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310547560.4A Pending CN103565827A (en) | 2013-11-07 | 2013-11-07 | Resveratrol-containing tablets |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103565827A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105078944A (en) * | 2014-05-11 | 2015-11-25 | 复旦大学 | Application of Isopaucifloral F in preparation of anti-osteoporosis drug |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1680240A (en) * | 2004-04-09 | 2005-10-12 | 汪云 | Composition containing resveratrol and soybean isoflavone and its preparation and use |
| CN101091720A (en) * | 2006-06-20 | 2007-12-26 | 上海多普富生物技术有限公司 | Health food with efficacy for preventing osteoporosis and preparation method |
-
2013
- 2013-11-07 CN CN201310547560.4A patent/CN103565827A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1680240A (en) * | 2004-04-09 | 2005-10-12 | 汪云 | Composition containing resveratrol and soybean isoflavone and its preparation and use |
| CN101091720A (en) * | 2006-06-20 | 2007-12-26 | 上海多普富生物技术有限公司 | Health food with efficacy for preventing osteoporosis and preparation method |
Non-Patent Citations (1)
| Title |
|---|
| 潘鸿章: "《化学与健康》", 30 June 2011, 北京师范大学出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105078944A (en) * | 2014-05-11 | 2015-11-25 | 复旦大学 | Application of Isopaucifloral F in preparation of anti-osteoporosis drug |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111467481A (en) | Composition for improving and/or preventing osteoarthritis and application thereof | |
| CN103584106A (en) | Composition capable of improving bone mineral density | |
| CN105124583A (en) | Health-care food capable of enhancing bone mineral density and preparation method thereof | |
| CN103565827A (en) | Resveratrol-containing tablets | |
| CN103565830A (en) | Composite calcium preparation | |
| CN103610755A (en) | Granules for treating osteoporosis | |
| CN103599186A (en) | Compound lotus root starch preparation | |
| CN103610740A (en) | Calcium chelate | |
| ES2543557T3 (en) | Effects of the association of vitamin K2 and vitamin D3 in the consolidation of a bone fracture | |
| CN103566355A (en) | Composite lotus root starch preparation | |
| CN103565930A (en) | Granule for increasing bone density | |
| CN103599096A (en) | Resveratrol tablet | |
| CN103599175A (en) | Granules for increasing bone density | |
| CN103599174A (en) | Composition for improving bone mineral density | |
| CN103599177A (en) | Composition for enhancing bone density | |
| CN103599521A (en) | Vitamin D complex granules | |
| CN103585457B (en) | A kind of medicament for the treatment of fracture | |
| CN103599525A (en) | Chelated calcium electuary | |
| CN103599168A (en) | Composition for enhancing bone density | |
| CN103611152A (en) | Compound vitamin D electuary | |
| CN103735613A (en) | Preparation for increasing bone mineral density | |
| CN103599524A (en) | Compound walnut powder solid preparation | |
| CN103598579A (en) | Health-care food containing soy isoflavone | |
| CN103585264A (en) | Preparation capable of increasing bone mineral density | |
| CN103599176A (en) | Composition for enhancing bone density |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C05 | Deemed withdrawal (patent law before 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140212 |